ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
Status:
Completed
Trial end date:
2011-06-02
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of ABI-008
given every 3 weeks; to characterize the toxicities of ABI-008; and to determine the
pharmacokinetic parameters for ABI-008 when given on an every-3-week schedule.